CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity?

• Verfasst von: Kvacskay, Peter [VerfasserIn]
• Verfasst von: Merkt, Wolfgang [VerfasserIn]
• Titel: CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity?
• Verf.angabe: Peter Kvacskay and Wolfgang Merkt
• E-Jahr: 2024
• Jahr: 09 March 2024
• Umfang: 2 S.
• Fussnoten: Gesehen am 09.08.2024
• Titel Quelle: Enthalten in: Rheumatology
• Ort Quelle: Oxford : Oxford Univ. Press, 1999
• Jahr Quelle: 2024
• Band/Heft Quelle: 63(2024), 9, Seite 2317-2318
• ISSN Quelle: 1462-0332
• DOI: doi:10.1093/rheumatology/keae144
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 189822921X

Abstract

Over recent months, a number of noteworthy case reports and small case series have reported safety and unprecedented efficacy for CD19-targeting Chimeric Antigen Receptor (CAR) T cell therapy in various severe and refractory autoimmune diseases. A new milestone in innovative, cell-based treatment in systemic autoimmunity is on the horizon. Treatment with CD19-targeting CAR T cells is now an established therapy in haematology, and it is increasingly being suggested for the treatment of various non-malignant diseases [1]. The first use of anti-CD19.CAR T cells in rheumatology was in a patient affected by severe SLE, and significant clinical and serological improvement was observed after the treatment [2].